Exploiting Pseudomonas putida for drug development.

Andreas Bechthold

doi:10.1016/j.chembiol.2005.02.008

Home/Archive/PubMed

PubMed · 15797207

Exploiting Pseudomonas putida for drug development.

Andreas Bechthold

View original source ↗Export metadata ↓

Abstract

In this issue of Chemistry & Biology, a strategy that combines large DNA fragment recombineering in Escherichia coli and heterologous expression in Pseudomonas putida is described. The work focuses on myxochromide S, a natural compound produced by Stigmatella aurantiaca.

Explore related subjects

DNA, Recombinant Drug Design Genes, Synthetic Genetic Engineering Proteobacteria Pseudomonas putida Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Andreas Bechthold. 2005. Exploiting Pseudomonas putida for drug development.. https://doi.org/10.1016/j.chembiol.2005.02.008

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Medical innovation, unmet medical needs, and the drug pipeline.

This paper outlines and illustrates the working of a theoretical approach from the social sciences for analyzing medical innovation, unmet medical need, and the drug pipeline. Using the social history of three drugs made from recombinant DNA (insulin, human growth hormone, and tissue-plasminogen activator) the paper shows how drugs can be both technically and organizationally efficient while the needs they satisfy can be created or identified. The paper posits that drugs that require more organizational efficiency tend to satisfy identified, rather then created needs. Key words: Recombinant DNA, technical efficiency, organizational efficiency, anthropology.

DNA, Recombinant↗

PubMed2006

Proteome analysis of mitochondrial outer membrane from Neurospora crassa.

The mitochondrial outer membrane mediates numerous interactions between the metabolic and genetic systems of mitochondria and the rest of the eukaryotic cell. We performed a proteomic study to discover novel functions of components of the mitochondrial outer membrane. Proteins of highly pure outer membrane vesicles (OMV) from Neurospora crassa were identified by a combination of LC-MS/MS of tryptic peptide digests and gel electrophoresis of solubilized OMV proteins, followed by their identification using MALDI-MS PMF. Among the 30 proteins found in at least three of four separate analyses were 23 proteins with known functions in the outer membrane. These included components of the import machinery (the TOM and TOB complexes), a pore-forming component (porin), and proteins that control fusion and fission of the organelle. In addition, proteins playing a role in various biosynthetic pathways, whose intracellular location had not been established previously, could be localized to the mitochondrial outer membrane. Thus, the proteome of the outer membrane can help in identifying new mitochondria-related functions.

DNA, Recombinant↗

PubMed2005

Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.

Gene transfer vectors based on adeno-associated virus (AAV) are now widely used in the field of gene therapy. These vectors have been studied for their potential use in treating many diseases, among them the muscular dystrophies, the most common of which is Duchenne muscular dystrophy (DMD). Several recent advances in the areas of AAV serotype analysis, transgene engineering, and vector delivery to muscle, together with novel means of rescuing mutant mRNA transcripts, have yielded impressive results in animal models of DMD. This minireview focuses on these recent advances and their implications for potential treatments for DMD and other neuromuscular disorders.

DNA, Recombinant↗